Alnylam Pharmaceuticals | ALNY - Cost Of Sales



Alnylam Pharmaceuticals reported $142.95M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
Acadia Pharmaceuticals USD 20.73M 342K Jun/2025
Agios Pharmaceuticals USD 1.7M 617K Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Amgen USD 3.01B 406M Jun/2025
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Incyte USD 78.77M 10.96M Jun/2025
Ionis Pharmaceuticals USD 4.15M 3.15M Jun/2025
Moderna USD 119M 29M Jun/2025
Neurocrine Biosciences USD 11.3M 2.1M Jun/2025
Novartis USD 3.32B 5M Jun/2025
PTC Therapeutics USD 15.48M 2.62M Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Sanofi EUR 2.99B 721M Jun/2025
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
Takeda JPY 384.68B 2.6B Jun/2025
Ultragenyx Pharmaceutical USD 23M 5.66M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025
Xencor 61.66M 50.95M Jun/2025